아토목세틴

아토목세틴
아토목세틴 구조식 이미지
카스 번호:
1643684-06-3
한글명:
아토목세틴
동의어(한글):
아토목세틴
상품명:
Atomoxetine EP Impurity C HCl
동의어(영문):
ATOMOXETINE;Atomoxetine EP Impurity C HCl;p-Tolyloxy Atomoxetine Hydrochloride;(R)-N-methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine;(R)-N-methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine hydrochloride;(R)-(-)-N-Methyl-3-phenyl-3-(p-tolyoxy)-propylamine hydrochloride;Atomoxetine Impurity 3 Hydrochloride(Atomoxetine EP Impurity C Hydrochloride);(R)-N-Methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine hydrochloride (Atomoxetine Impurity)
CBNumber:
CB7346828
분자식:
C17H21NO
포뮬러 무게:
255.35
MOL 파일:
Mol file

아토목세틴 속성

산도 계수 (pKa)
pKa 10.1 (Uncertain)

안전

아토목세틴 C화학적 특성, 용도, 생산

용도

p-Tolyloxy Atomoxetine Hydrochloride is an impurity of Atomoxetine Hydrochloride(A791400) which is a norepinephrine reuptake inhibitor.

Pharmacokinetics

Atomoxetine is well absorbed from the GItract and cleared primarily by metabolism, with the majority of the dose being excreted into the urine. Atomoxetine is metabolized primarily by CYP2D6 to its major active metabolite, 4-hydroxyatomoxetine, which is eliminated as its glucuronide. Peak plasma concentrations of atomoxetine occur 1 to 2 hours after oral administration. Significant differences are seen in the elimination half-life between normal metabolizers, extensive metabolizers, and poor metabolizers. Atomoxetine exhibited an elimination half-life of 3 to 6 hours for normal and extensive metabolizers and 17 to 21 hours for poor metabolizers. CYP2C19 is the other enzyme primarily responsible for the formation of its minor metabolite N-desmethylatomoxetine.

Clinical Use

Atomoxetine is used as a safe and well-tolerated “nonstimulant” treatment of ADHD in both adults and children and of depression. Among children and adolescents aged 8 to 18 years, atomoxetine was superior to placebo in reducing symptoms of ADHD and in improving social and family functioning symptoms. Oral atomoxetine is promoted as an alternative to conventional ADHD therapy with methylphenidate, dextroamphetamine, and pemoline. It also can be a replacement for bupropion or for TCAs. Onset of action is approximately 7 days.

부작용

At therapeutic doses, no serious drug-related adverse effects have been encountered. Adverse effects have included modest increases in diastolic blood pressure and heart rate, anorexia, weight loss, somnolence, dizziness, GI effects (nausea), dry mouth, and skin rash.

효소 저해제

This ADHD drug (FWfree-base = 255.36 g/mol; FWhydrochloride = 291.81 g/mol; CAS 83015-26-3), also known as LY139603, Strattera?, and systematically as (3R) -N-methyl-3- (2-methylphenoxy) -3-phenylpropan-1-amine; (R) -N- methyl-3-phenyl-3- (o-tolyloxy) -propan-1-amine, potently inhibits the presynaptic norepinephrine transporter, Ki = 4.5 nM and is used to treat depression and attention-deficit/hyperactivity disorder. In 2002, Strattera became the first FDA-approved nonstimulant for the treatment of ADHD. The mechanism of action is related to its selective inhibition of presynaptic norepinephrine reuptake in the prefrontal cortex. Atomoxetine demonstrates high affinity and selectivity for norepinephrine transporters, but little or no affinity for neurotransmitter receptors. Atomoxetine demonstrates preferential binding to areas of known high distribution of noradrenergic neurons, such as the fronto-cortical subsystem. Atomoxetine undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP2D6) in a small percentage of the population. (Note: Atomoxetine was originally named tomoxetine, but was changed to avoid any potential confusion with tamoxifen.) Key Pharmacokinetic Parameters: See Appendix II in Goodman & Gilman’s THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 12th Edition (Brunton, Chabner & Knollmann, eds.) McGraw-Hill Medical, New York.

아토목세틴 준비 용품 및 원자재

원자재

준비 용품


아토목세틴 공급 업체

글로벌( 35)공급 업체
공급자 전화 이메일 국가 제품 수 이점
China National Standard Pharmaceutical Corporation Limited
+8615391658522
overseasales@yongstandards.com China 11927 58
Beijing Comparison Pharmaceutical Technology Co., Ltd 010-010-52878169 15801002657
sales@bjcomparison.com China 4921 58
ChemStrong Scientific Co.,Ltd 0755-0755-66853366 13670046396
sales@chem-strong.com China 18021 56
ShangHai Biochempartner Co.,Ltd 17754423994 17754423994
2853530910@QQ.com China 8014 62
Hubei Yangxin Medical Technology Co., Ltd. 15374522761
3003392093@qq.com China 8346 55
Guangzhou Dreampharm Biotechnology Co., Ltd. 020-36607679 17825480238
3008233717@qq.com China 9919 12
Jinan blalong chemical co. LTD 2710913286@.com
1513643261@qq.com China 14253 58
Shenzhen ruikai de biotechnology co., ltd. 0755-61348847 17820674378
2682116078@qq.com China 7844 58
Nanjing wangzhixing Pharmaceutical Technology Co., Ltd 15850510341
shiqingran@wzxchem.com China 3675 58
Cato Research Chemicals Inc. 020-81215950 4000-868-328
customer@uwalab.com United States 10413 58

Copyright 2019 © ChemicalBook. All rights reserved